The estimated Net Worth of Cary Sucoff is at least $64.8 mil dollars as of 20 December 2023. Mr. Sucoff owns over 3,333 units of ContraFect Corp stock worth over $2,318 and over the last 10 years he sold CFRX stock worth over $0. In addition, he makes $62,479 as Independent Director at ContraFect Corp.
Sign up
Mr. Sucoff CFRX stock SEC Form 4 insiders trading
Cary has made over 10 trades of the ContraFect Corp stock since 2016, according to the Form 4 filled with the SEC. Most recently he exercised 3,333 units of CFRX stock worth $773 on 20 December 2023.
The largest trade he's ever made was exercising 250,000 units of ContraFect Corp stock on 9 February 2016 worth over $192,500. On average, Cary trades about 20,639 units every 120 days since 2015. As of 20 December 2023 he still owns at least 10,000 units of ContraFect Corp stock.
You can see the complete history of Mr. Sucoff stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Cary Sucoff biography
Cary W. Sucoff J.D. serves as Independent Director of the Company. Mr. Sucoff has more than 30 years of securities industry experience encompassing supervisory, banking and sales responsibilities. He has participated in the financing of more than 100 public and private biotech companies. Since 2011, Mr. Sucoff has owned and operated Equity Source Partners LLC, an advisory and consulting firm. In addition to ContraFect, Mr. Sucoff currently serves on the board of directors of Legacy Education Alliance and First Wave Technologies, Inc. In addition, Mr. Sucoff currently serves as a consultant to Sapience Therapeutics and Galimedix Pharmaceuticals Inc. Mr. Sucoff is the past President of New England Law/Boston, has been a member of the Board of Trustees for over 25 years and is the current Chairman of the Endowment Committee. Mr. Sucoff received a B.A. from SUNY Binghamton in 1974 and a J.D. from New England School of Law in 1977, where he was managing editor of the Law Review and graduated magna cum laude. He has been a member of the Bar of the State of New York since 1978.
What is the salary of Cary Sucoff?
As the Independent Director of ContraFect Corp, the total compensation of Cary Sucoff at ContraFect Corp is $62,479. There are 12 executives at ContraFect Corp getting paid more, with Roger Pomerantz having the highest compensation of $1,875,610.
How old is Cary Sucoff?
Cary Sucoff is 68, he's been the Independent Director of ContraFect Corp since 2010. There are 2 older and 14 younger executives at ContraFect Corp. The oldest executive at ContraFect Corp is Sol Barer, 72, who is the Lead Independent Director.
What's Cary Sucoff's mailing address?
Cary's mailing address filed with the SEC is C/O IMAC HOLDINGS, INC., 1605 WESTGATE CIRCLE, BRENTWOOD, TN, 37027.
Insiders trading at ContraFect Corp
Over the last 10 years, insiders at ContraFect Corp have traded over $2,523,392 worth of ContraFect Corp stock and bought 525,578 units worth $426,359 . The most active insiders traders include Sol J Barer, Roger Pomerantz y Industrial Co., Ltd Fosun. On average, ContraFect Corp executives and independent directors trade stock every 70 days with the average trade being worth of $16,159. The most recent stock trade was executed by Michael Messinger on 13 December 2019, trading 5,000 units of CFRX stock currently worth $1,850.
What does ContraFect Corp do?
we are a biotechnology company focused on protein and antibody therapeutic products for life-threatening infectious diseases, particularly those treated in hospital-based settings. due to drug-resistant and newly-emerging pathogens, infections in the hospital are already the fourth leading cause of death in the united states, following heart disease, cancer and stroke. we address multi-drug resistant infections using our therapeutic products from our lysin and monoclonal antibody platforms to target the conserved regions of either bacteria or viruses. our strategy is to use our first in class therapies to achieve a leadership position in the treatment of life-threatening infectious diseases, including drug-resistant pathogens. we plan to pursue commercialization of therapeutic products through discovery, acquisition and development of protein and antibody products. our novel lysins are enzymes that are produced in the life cycle stage of bacteriophage, a virus that infects and kills ba
What does ContraFect Corp's logo look like?
Complete history of Mr. Sucoff stock trades at ContraFect Corp y IMAC Inc
ContraFect Corp executives and stock owners
ContraFect Corp executives and other stock owners filed with the SEC include:
-
Roger Pomerantz,
Chairman of the Board, Chief Executive Officer -
Dr. Roger James Pomerantz F.A.C.P., FACP, M.D.,
Chairman, CEO & Pres -
Dr. Roger James Pomerantz FACP, M.D., F.A.C.P.,
Chairman, CEO & Pres -
Cara Cassino,
Executive Vice President - Research and Development, Chief Medical Officer -
Dr. Cara M. Cassino,
Chief Medical Officer and Exec. VP of R&D -
Natalie Bogdanos,
General Counsel, Corporate Secretary -
Michael Messinger CPA, CPA,
Chief Financial Officer -
Michael Messinger,
Chief Financial Officer -
Nancy Dong,
Vice President - Finance and Administration -
Sol Barer,
Lead Independent Director -
David Low,
Independent Director -
Michael Otto,
Independent Director -
Cary Sucoff,
Independent Director -
Lishan Aklog,
Director -
Jane Ambler,
Vice President - Clinical Microbiology -
Dr. Michael Wittekind Ph.D.,
Consultant -
Dr. Gary Woodnutt,
Sr. VP of Translational Sciences & Preclinical Devel. -
Dr. Michael Wittekind,
Consultant -
Natalie Bogdanos J.D.,
Gen. Counsel, Corp. Sec. & Data Protection Officer -
Isaac Blech,
Director -
Daniel Couto,
SVP Manufacturing & Facilities -
Joshua B Muntner,
SVP Business Development -
Julia P Gregory,
CEO -
Michael G. Wittekind,
Chief Scientific Officer -
Steven C Gilman,
Director -
Lisa Ricciardi,
Director -
Fosun Pharmaceutical (Group...,
10% owner -
Industrial Co., Ltd Fosun,
10% owner -
David B. Huang,
Chief Medical Officer -
Shengda Zan,
Director -
Barry J. Kappel,
SVP Business Development -
David A Scheinberg,
Director -
W Moody Revocable Trust Ernest,
10% owner -
Jane F Barlow,
Director